Clinical trial NCT05755698: Emotional Awareness and Expression Therapy (EAET) for Migraine
Official title: Evaluation of Emotional Awareness and Expression Therapy (EAET) As a Novel Migraine Treatment
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Migraine Disorders
Lead sponsor: University of Utah
Sponsor class: OTHER
Collaborators: name: Wayne State University
First posted: 2023-03-06
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The investigators will form groups of five participants with migraine who will experience a group-based EAET intervention.
Primary purpose: TREATMENT

Brief summary: The goal of this feasibility study is to test the effect of a new behavioral intervention, Emotional Awareness and Expression Therapy (EAET), as a possible new treatment for people living with migraine.

The main questions it aims to answer are:

* Can EAET lower the frequency and severity of migraine attacks?
* What are the elements that can explain EAET's effect?

Requirements from Participants:

* Participants will engage in 8 weekly online sessions via zoom (sessions are 2 hours long). Each session has a lecture, in-class exercises, discussion, and weekly assignments.
* Each participant is required to fill out questionnaires before the first session, after the last session of the treatment, and at a 3-month follow-up after treatment.

Participants will benefit from a new and promising intervention that can significantly help with their migraines at no cost.

Detailed description: Migraine is a debilitating disorder that affects many people worldwide. Despite the new migraine medications and the recommended complementary interventions for migraine, most people living with migraine are not migraine-free and continue to experience debilitating headaches. Chronic stress and past traumatic experiences are known to contribute to the development of migraine and to the transition from episodic to chronic migraine. Although current behavioral interventions focus on "calming down" the body and mind, a different approach is to help individuals identify and express difficult emotions, release emotionally difficult experiences, and acquire new skills to help manage interpersonal relationships. Emotional Awareness and Expression Therapy (EAET) is a new intervention that focuses on this approach and has shown promising results in patients with different chronic pain conditions. In this research, the investigators will test how effective EAET is in people living with migraine.

Eligibility criteria: Inclusion Criteria:

* Adults of all genders, ages 18-80.
* A diagnosis of either episodic or chronic migraine (with or without aura) by a licensed neurologist.
* A migraine disability assessment scores higher than 6.
* A stable medication regimen for a minimum of 3 months.
* Must have had migraines for at least 1 year.
* Must have a minimum of 4 migraine days per month.

Exclusion Criteria:

* Serious psychiatric disorders (e.g., schizophrenia or bipolar disorder) uncontrolled with medications.
* Active suicidal ideation.
* Risk of violent behavior.
* Untreated alcohol or substance use disorder.
* Substantial cognitive impairment.
* A diagnosis of medication overuse headaches.
* Changes in migraine medication in the past 3 months.
* Enrollment in another treatment study.
* Current involvement in health-related litigation or disability application.
* Inability to use a computer and/or smartphone.
* limited access to the internet.
* Inability to communicate in English.
* Failure to complete at least 80% of the daily diaries during the baseline 30-day diary assessment.

Primary outcomes:
measure: Number of migraine days in a month at baseline.
timeFrame: 1 month before the treatment.
measure: Change in the number of migraine days in a month after treatment compared to baseline.
timeFrame: 8 weeks after commencement of treatment.
Secondary outcomes:
measure: Migraine effects on quality of life at baseline.
timeFrame: 1 week before the treatment.
measure: Change in migraine effects on quality of life after treatment compared to baseline.
timeFrame: 8 weeks after commencement of treatment.
measure: Change in migraine effects on quality of life at 3 month followup compared to baseline.
timeFrame: 3 months after the end of the treatment.
measure: Allodynia levels at baseline.
timeFrame: 1 week before the treatment.
measure: Change in allodynia after treatment compared to baseline.
timeFrame: 8 weeks after commencement of treatment.
measure: Change in allodynia at 3 months followup compared to baseline.
timeFrame: At 3 months followup after the end of treatment.
measure: Anxiety levels at baseline.
timeFrame: 1 week before treatment
measure: Change in anxiety levels after treatment compared to baseline.
timeFrame: 8 weeks after commencement of treatment.
measure: Change in anxiety levels at 3 months followup compared to baseline.
timeFrame: At 3 months followup from the end of treatment.
measure: Depression levels at baseline.
timeFrame: 1 week before treatment.
measure: Change in depression after treatment compared to baseline.
timeFrame: 8 weeks after commencement of treatment.
measure: Change in depression at three months followup compared to baseline.
timeFrame: At 3 months followup after end of treatment.
measure: Emotional coping at baseline.
timeFrame: 1 week before treatment.
measure: Change in emotional coping after treatment compared to baseline.
timeFrame: 8 weeks after commencement of treatment.
measure: Change in emotional coping at three months followup compared to baseline.
timeFrame: At three months followup after end of treatment
measure: Positive and negative affect at baseline
timeFrame: 1 week before treatment.
measure: Changes in positive/negative affect at the end of treatment compared to baseline
timeFrame: 8 weeks after commencement of treatment.
measure: Changes in positive/negative affect at 3-months followup compared to baseline.
timeFrame: At 3 months followup after treatment.
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: Dan Kaufmann
state: Utah
Study officials:
References:
citation: Geumei AM, Mahfouz M, Aboul-Enein A. Intrahepatic vascular pathways: Hepatic arterioportal shunt. J Surg Res. 1968 Oct;8(10):463-70. doi: 10.1016/0022-4804(68)90109-1. No abstract available.
citation: Yarns BC, Lumley MA, Cassidy JT, Steers WN, Osato S, Schubiner H, Sultzer DL. Emotional Awareness and Expression Therapy Achieves Greater Pain Reduction than Cognitive Behavioral Therapy in Older Adults with Chronic Musculoskeletal Pain: A Preliminary Randomized Comparison Trial. Pain Med. 2020 Nov 1;21(11):2811-2822. doi: 10.1093/pm/pnaa145.